(Q38033767)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22883508%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

title

New drugs, procedures, and devices for hypertension (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22883508%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

main subject

arterial hypertension

0 references

author

Markus P. Schlaich

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22883508%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

Stéphane Laurent

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22883508%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Murray Esler

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22883508%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

language of work or name

English

0 references

publication date

1 August 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22883508%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22883508%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

volume

380

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22883508%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

page(s)

591-600

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22883508%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

issue

9841

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22883508%20AND%20SRC:MED&resulttype=core&format=json

2007 Guidelines for the Management of Arterial Hypertension

10 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Resistant hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Point: Chronic Activation of the Sympathetic Nervous System is the Dominant Contributor to Systemic Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Inhibition of zinc metallopeptidases in cardiovascular disease--from unity to trinity, or duality?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Antihypertensive effects of fasidotril, a dual inhibitor of neprilysin and angiotensin-converting enzyme, in rats and humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Vasopeptidase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Vasopeptidase inhibition: a double-edged sword?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Endothelin-Converting Enzyme/Neutral Endopeptidase Inhibitor SLV338 Prevents Hypertensive Cardiac Remodeling in a Blood Pressure–Independent Manner

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

New aspects of rapid aldosterone signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

1 reference

7 January 2021

Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Nitrosyl-cobinamide, a new and direct nitric oxide releasing drug effective in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

New NO-Releasing Pharmacodynamic Hybrids of Losartan and Its Active Metabolite: Design, Synthesis, and Biopharmacological Properties

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

WB1106, a novel nitric oxide-releasing derivative of telmisartan, inhibits hypertension and improves glucose metabolism in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Treatment of patients with hypertension and arthritis pain: new concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Signal transduction of the (pro)renin receptor as a novel therapeutic target for preventing end-organ damage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Chronic activation of endogenous angiotensin-converting enzyme 2 protects diabetic rats from cardiovascular autonomic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Active immunization against renin in normotensive marmoset

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Next generation multifunctional angiotensin receptor blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Vascular aging: A tale of EVA and ADAM in cardiovascular risk assessment and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Improved arterial compliance by a novel advanced glycation end-product crosslink breaker

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Results of bilateral supradiaphragmatic splanchnicectomy for arterial hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Chronic carotid sinus nerve stimulation in the treatment of essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Graded blood pressure reduction in hypertensive outpatients associated with use of a device to assist with slow breathing.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Obstructive sleep apnoea and its cardiovascular consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Deep brain stimulation: a new treatment for hypertension?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

An implantable carotid sinus stimulator for drug-resistant hypertension: surgical technique and short-term outcome from the multicenter phase II Rheos feasibility trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Posterior fossa neurovascular anomalies in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Translational medicine: the antihypertensive effect of renal denervation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

CPAP for the metabolic syndrome in patients with obstructive sleep apnea.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

The role of aldosteronism in causing obesity-related cardiovascular risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Efficacy of spironolactone therapy in patients with true resistant hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Deep brain stimulation of the periaqueductal grey induces vasodilation in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Amplified respiratory-sympathetic coupling in the spontaneously hypertensive rat: does it contribute to hypertension?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Effect of device-guided breathing exercises on blood pressure in patients with hypertension: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Functional organisation of central cardiovascular pathways: studies using c-fos gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Neurovascular decompression of the rostral ventrolateral medulla decreases blood pressure and sympathetic nerve activity in patients with refractory hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Renal vein renin ratios and collateral vessels in renovascular hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Clinical outcomes after percutaneous revascularization versus medical management in patients with significant renal artery stenosis: A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Revascularization versus medical therapy for renal-artery stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Systemic and renal-specific sympathoinhibition in obesity hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Implantable carotid sinus stimulator for the treatment of resistant hypertension: local effects on carotid artery morphology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Micro-anatomy of the renal sympathetic nervous system: a human postmortem histologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Neural control of renal function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Catheter-based renal sympathetic denervation: chronic preclinical evidence for renal artery safety

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Renal sympathetic-nerve ablation for uncontrolled hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Renal afferent denervation prevents hypertension in rats with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Sympathetic overactivity in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

Renal denervation in moderate to severe CKD.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960825-3

7 January 2021

10.1016/S0140-6736(12)60825-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22883508%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference